35 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
19 Apr 24
Current report (foreign)
6:12am
dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently. Liver Injury: There have been reports … of significant liver injury. Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all
6-K
TAK
Takeda Pharmaceutical Co
28 Sep 23
Current report (foreign)
6:17am
, withhold dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
Liver Injury: There have been reports … evidence of significant liver injury.
Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
Takeda is an initiative launched in 2015 to promote a safer workplace, with the goal of reducing our Lost Time Injury Frequency Rate (LTIFR) by 30 … 3 2.69 2 1 0.76 0 FY13 FY14 FY15 FY16 FY17 FY18 Total Occupational Injury Frequency Rate1 Lost Time Injury Frequency Rate2 1 INCLUDING THOSE WITHOUT
6-K
TAK
Takeda Pharmaceutical Co
8 Dec 22
Current report (foreign)
6:46am
injection. It is important that precautions are in place to avoid injury from fainting. A protective immune response with Qdenga may not be elicited
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
23 Aug 22
Current report (foreign)
6:13am
are in place to avoid injury from fainting. A protective immune response with QDENGA may not be elicited in all vaccinees against all serotypes of dengue
S-8
EX-99.1
9gi69ov2
29 Jun 22
Registration of securities for employees
6:13am
6-K
EX-99.1
blvea 0pl5ilxk
6 Apr 21
Current report (foreign)
6:29am
20FR12B/A
EX-10.13
9trzl348sgk
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
EX-10.13
k0twcipbc 6ug4l1bjh
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
20FR12B/A
EX-10.14
3wwd3 j1xma1ab
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
EX-10.14
7tl mmcfwz4m7xz7uwb
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
6-K
EX-99.1
d7bbaf6i zt6xig
17 Dec 20
Current report (foreign)
6:01am
6-K
EX-99.1
5x1f4
21 Nov 19
Current report (foreign)
6:08am
6-K
EX-99.1
ts779q1q36qhvj lz4
14 Nov 19
Current report (foreign)
6:26am
20FR12B/A
EX-10.7
mzy 3t0bix
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
DRS/A
EX-10.7
51q9jj n09dwqe2z
16 Nov 18
Draft registration statement (amended)
12:00am
DRS/A
EX-10.9
926wdc
16 Nov 18
Draft registration statement (amended)
12:00am
20FR12B
EX-10.9
kln31deayte
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
20FR12B/A
EX-10.9
2stm8f gq6rhgn
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
DRS/A
EX-10.5
xs3twcfj3fnxp ehkkl2
16 Nov 18
Draft registration statement (amended)
12:00am